Treatment with Tecfidera (dimethyl fumarate) significantly reduces relapse rates for people with multiple sclerosis (MS), and most MS patients on the approved therapy remain free from disability progression for several years.
That’s according to a final analysis from the Phase 4 ESTEEM clinical trial (NCT02047097), which tracked outcomes from Tecfidera treatment among more than 5,100 MS patients. The results also did not reveal any unexpected safety issues with the long-approved therapy, the researchers noted. Read full story HERE.